“Lipofectamine-Mediated CRISPR-Cas9 Delivery Targeting the mecA Gene in Methicillin-Resistant Staphylococcus aureus: A Novel Approach to Reverse Antibiotic Resistance”, WAJHN, vol. 2, no. 2, pp. 27–35, Jun. 2026, doi: 10.63954/bantev40.